Role of cancer stem in determining radiosensitivity in vitro and in vivo
| Project/Area Number |
24591860
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | National Cancer Center Japan |
|---|
Principal Investigator |
Akimoto Tetsuo 国立研究開発法人国立がん研究センター, 先端医療開発センター, 分野長 (10261851)
|
|---|
| Project Period (FY) |
2012-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Keywords | 放射線感受性 / がん幹細胞 / 放射線抵抗性 / 放射線生物学 / 放射線治療 / HPV感染 / 頭頚部癌 / 治療抵抗性 / 頭頸部癌 / 放射線応答 / 放射線生物 |
|---|
| Outline of Final Research Achievements |
The main purpose of this study is to establish effective radiosensitizing approach based in the role of cancer stem cells in determining radiosensitivity and/or cellular response to cancer cells. In 2013 and 2014, we performed basic research using cultured cancer cells, and then, we investigated the correlation between clinical outcomes after definitive IMRT for oropharyngeal cancer and the expression of p16 and CD44, cancer stem cell marker. Finally, we demonstrated that the PFS and LRC rates in the CD44(-) patients (86% and 93%, respectively) were significantly higher than those in the CD44(+) patients (57% and 70%, respectively), and concluded that profiling of CD44 and p16 protein expressions by immunohistochemical staining is useful for predicting the treatment outcomes in patients with OPSCC undergoing definitive intensity modulated radiation therapy.
|
Report
(5 results)
Research Products
(19 results)
-
-
-
[Journal Article] Neuropathic Pain Features in Patients with Bone Metastases2016
Author(s)
Nakamura N, Takahashi O, Zenda S, Kawamori J, Ogita M, Onozawa M, Arahira S, Toshima M, Motegi A, Hirano Y, Hojo H, Akimoto T
-
Journal Title
Clin Oncol (R Coll Radiol)
Volume: 28
Pages: 204-208
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
-
[Journal Article] Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706)2015
Author(s)
ahara M, Kiyota N, Mizusawa J, Nakamura K, Hayashi R, Akimoto T, Hasegawa Y, Iwae S, Monden N, Matsuura K, Fujii H, Onozawa Y, Homma A, Kubota A, Fukuda H, Fujii M.
-
Journal Title
Cancer Sci
Volume: 12
Pages: 132-136
DOI
Related Report
Peer Reviewed / Open Access
-
-
[Journal Article] Working Subgroup of Urological Cancers in Japanese Radiation Oncology Study Group. Patterns of practice in the radiation therapy for bladder cancer: survey of the Japanese Radiation Oncology Study Group (JROSG).2014
Author(s)
5.Maebayashi T, Ishikawa H, Yorozu A, Yoshida D, Katoh H, Nemoto K, Ishihara S, Takemoto S, Ishibashi N, Tokumaru S, Akimoto T;
-
Journal Title
Jpn J Clin Oncol
Volume: 44(11):
Pages: 1109-15
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
[Journal Article] Phase II Study of Cetuximab Plus Concomitant Boost Radiotherapy in Japanese Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.2013
Author(s)
1. Okano S, Yoshino T, Fujii M, Onozawa Y, Kodaira T, Fujii H, Akimoto T, Ishikura S, Oguchi M, Zenda S, de Blas B, Tahara M
-
Journal Title
Jpn J Clin Oncol
Volume: 43(5)
Pages: 476-82
Related Report
Peer Reviewed
-
[Journal Article] Pancreatic resection for metastatic melanoma originating from the nasal cavity: a case report and literature review2013
Author(s)
2. Sugimoto M, Gotohda N, Kato Y, Takahashi S, Kinoshita T, Shibasaki H, Kojima M, Ochiai A, Zenda S, Akimoto T, Konishi M
-
Journal Title
Anticancer Res
Volume: 33(2)
Pages: 567-73
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
